摘要
[目的]研究基质金属蛋白酶鄄9在淋巴结阴性乳腺癌中的表达及预后意义。[方法]对1990～1998年收治的270例淋巴结阴性乳腺癌患者肿瘤标本,用免疫组织化学方法检测肿瘤细胞基质金属蛋白酶鄄9(MMP鄄9)的表达。进一步分析基质金属蛋白酶的表达与其他临床病理预后指标的相关性。单因素检测基质金属蛋白酶的表达作为预后指标对无复发生存率和总生存率的重要性。[结果]肿瘤标本MMP鄄9阳性率为59.6%(161/270),MMP鄄9的表达与肿瘤病理分级呈正相关(P<0.05)。单因素分析MMP鄄9阳性表达患者有较低的无复发生存率(P<0.05),但和总生存率无关。[结论]淋巴结阴性乳腺癌患者MMP鄄9表达是预后较差的指标。
To study the expression of MMP-9 in lymph node-negative breast carcinoma and its relationship with prognosis. Tumor specimens from 270 cases of primary breast carcinoma with negative axillary node 1990 to 1998 were studied. MMP-9 protein expression in breast carcinoma tissues was detected immunohistochemically. We analyzed the association of MMP-9 expression with other clinic-pathological factors by chi-square test. Univariate analysis was performed to evaluate the prognostic significance of MMP-9 expression in progress free survival and overall survival. Positive rate of MMP-9 immunostaining in tumor specimens was 59.6% (161/270), it revealed positive correlation with tumor grading(P<0.05). In univariate analysis, MMP-9 was significantly related to progress free survival (P<0.05), but not to overall survival. [Conclusion] MMP-9 expression is an indicator for worse prognosis in patient of breast carcinoma with negative node.
出处
《肿瘤学杂志》
CAS
2004年第6期410-412,共3页
Journal of Chinese Oncology
关键词
乳腺肿瘤
基质金属蛋白酶-9
淋巴结
预后
breast neoplasms
matrix-metalloproteinase-9
lymph node
prognosis
